318 related articles for article (PubMed ID: 25023650)
1. Physician variation in management of low-risk prostate cancer: a population-based cohort study.
Hoffman KE; Niu J; Shen Y; Jiang J; Davis JW; Kim J; Kuban DA; Perkins GH; Shah JB; Smith GL; Volk RJ; Buchholz TA; Giordano SH; Smith BD
JAMA Intern Med; 2014 Sep; 174(9):1450-9. PubMed ID: 25023650
[TBL] [Abstract][Full Text] [Related]
2. Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer.
Tyson MD; Graves AJ; O'Neil B; Barocas DA; Chang SS; Penson DF; Resnick MJ
JAMA Surg; 2017 Jan; 152(1):27-34. PubMed ID: 27653425
[TBL] [Abstract][Full Text] [Related]
3. Physician visits prior to treatment for clinically localized prostate cancer.
Jang TL; Bekelman JE; Liu Y; Bach PB; Basch EM; Elkin EB; Zelefsky MJ; Scardino PT; Begg CB; Schrag D
Arch Intern Med; 2010 Mar; 170(5):440-50. PubMed ID: 20212180
[TBL] [Abstract][Full Text] [Related]
4. Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US.
Washington SL; Jeong CW; Lonergan PE; Herlemann A; Gomez SL; Carroll PR; Cooperberg MR
JAMA Netw Open; 2020 Dec; 3(12):e2031349. PubMed ID: 33369661
[TBL] [Abstract][Full Text] [Related]
5. Variation in the use of active surveillance for low-risk prostate cancer.
Löppenberg B; Friedlander DF; Krasnova A; Tam A; Leow JJ; Nguyen PL; Barry H; Lipsitz SR; Menon M; Abdollah F; Sammon JD; Sun M; Choueiri TK; Kibel AS; Trinh QD
Cancer; 2018 Jan; 124(1):55-64. PubMed ID: 28902401
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1).
Schymura MJ; Kahn AR; German RR; Hsieh MC; Cress RD; Finch JL; Fulton JP; Shen T; Stuckart E
BMC Cancer; 2010 Apr; 10():152. PubMed ID: 20403178
[TBL] [Abstract][Full Text] [Related]
7. Association between urologist characteristics and radiation oncologist consultation for patients with locoregional prostate cancer.
Quek RG; Ward KC; Master VA; Lin CC; Portier KM; Virgo KS; Lipscomb J
J Natl Compr Canc Netw; 2015 Mar; 13(3):303-9. PubMed ID: 25736007
[TBL] [Abstract][Full Text] [Related]
8. Population-Based Assessment of Determining Treatments for Prostate Cancer.
Chamie K; Williams SB; Hu JC
JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
[TBL] [Abstract][Full Text] [Related]
9. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer.
Fowler FJ; McNaughton Collins M; Albertsen PC; Zietman A; Elliott DB; Barry MJ
JAMA; 2000 Jun; 283(24):3217-22. PubMed ID: 10866869
[TBL] [Abstract][Full Text] [Related]
10. Recommendations of Active Surveillance for Intermediate-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists.
Kim SP; Shah ND; Meropol NJ; Tilburt JC; Nguyen PL; Yu JB; Abouassaly R; Kim A; Gross CP
Eur Urol Oncol; 2019 Mar; 2(2):189-195. PubMed ID: 31017095
[TBL] [Abstract][Full Text] [Related]
11. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
12. Urologists' referral and radiation oncologists' treatment patterns regarding high-risk prostate cancer patients receiving radiotherapy within 6 months after radical prostatectomy: A prospective cohort analysis.
Egger S; Smith DP; Brown BB; Kneebone AB; Dominello A; Brooks AJ; Young J; Xhilaga M; Haines M; O'Connell DL
J Med Imaging Radiat Oncol; 2020 Feb; 64(1):134-143. PubMed ID: 31793211
[TBL] [Abstract][Full Text] [Related]
13. Physician-Driven Variation in Nonrecommended Services Among Older Adults Diagnosed With Cancer.
Lipitz-Snyderman A; Sima CS; Atoria CL; Elkin EB; Anderson C; Blinder V; Tsai CJ; Panageas KS; Bach PB
JAMA Intern Med; 2016 Oct; 176(10):1541-1548. PubMed ID: 27533635
[TBL] [Abstract][Full Text] [Related]
14. Physician social networks and variation in prostate cancer treatment in three cities.
Pollack CE; Weissman G; Bekelman J; Liao K; Armstrong K
Health Serv Res; 2012 Feb; 47(1 Pt 2):380-403. PubMed ID: 22092259
[TBL] [Abstract][Full Text] [Related]
15. Association of reimbursement policy and urologists' characteristics with the use of medical androgen deprivation therapy for clinically localized prostate cancer.
Quek RG; Master VA; Portier KM; Ward KC; Lin CC; Virgo KS; Lipscomb J
Urol Oncol; 2014 Aug; 32(6):748-60. PubMed ID: 24840868
[TBL] [Abstract][Full Text] [Related]
16. Variation in use of active surveillance among men undergoing expectant treatment for early stage prostate cancer.
Filson CP; Schroeck FR; Ye Z; Wei JT; Hollenbeck BK; Miller DC
J Urol; 2014 Jul; 192(1):75-80. PubMed ID: 24518783
[TBL] [Abstract][Full Text] [Related]
17. United States radiation oncologists' and urologists' opinions about screening and treatment of prostate cancer vary by region.
McNaughton Collins M; Barry MJ; Zietman A; Albertsen PC; Talcott JA; Walker Corkery E; Elliott DB; Fowler FJ
Urology; 2002 Oct; 60(4):628-33. PubMed ID: 12385923
[TBL] [Abstract][Full Text] [Related]
18. Expectant management of veterans with early-stage prostate cancer.
Filson CP; Shelton JB; Tan HJ; Kwan L; Skolarus TA; Saigal CS; Litwin MS
Cancer; 2016 Feb; 122(4):626-33. PubMed ID: 26540451
[TBL] [Abstract][Full Text] [Related]
19. Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer.
Shavers VL; Brown M; Klabunde CN; Potosky AL; Davis W; Moul J; Fahey A
Med Care; 2004 Mar; 42(3):239-50. PubMed ID: 15076823
[TBL] [Abstract][Full Text] [Related]
20. Utilization of Active Surveillance and Watchful Waiting for localized prostate cancer in the daily practice.
Herden J; Weissbach L
World J Urol; 2018 Mar; 36(3):383-391. PubMed ID: 29330583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]